Authors

  • Iriskulov B.U., Musaev Kh.A.

Keywords:

immunoglobulins, intestinal barrier, gut microbiota, endotoxemia, ceftriaxone, high-fat diet, alkaline phosphatase, gamma-glutamyl transferase, fatty liver.

References

1. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology. 2023;79(6):1542–1556. https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext

2. Zhou J., Tripathi M., Sinha R.A., et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver disease. Journal of Gastrointestinal Surgery. 2022;26(3):671–683. https://pubmed.ncbi.nlm.nih.gov/34734369/

3. Wang R., Tang R., Li B., et al. Contribution of the gut–liver axis to immune signaling pathways in NAFLD. Frontiers in Immunology. 2022;13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471422/

4. Sharma A., Nagalli S., et al. Serum immunoglobulin A levels and nonalcoholic fatty liver disease. Canadian Liver Journal. 2018;1(4).

5. Mouzaki M., Bass L.M., et al. Serum immunoglobulin A levels do not correlate with liver disease severity in children with nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2018;68(2). https://pubmed.ncbi.nlm.nih.gov/30363043/

6. Nier A., Engstler A.J., Maier I.B., Bergheim I. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2017;23(4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292346/

7. Ferolla S.M., Armiliato G.N., Couto C.A., Ferrari T.C. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: what do we know in 2023? Nutrients. 2023;15(6). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052062/

8. Pezzino S., Sofia M., Faletra G., et al. The gut–liver axis and nonalcoholic fatty liver disease: a vicious cycle of dysfunction orchestrated by the gut microbiome. Biology. 2022;11(11):1622. https://doi.org/10.3390/biology11111622

9. Kolaric T.O., Nincevic V., Kuna L., et al. NAFLD/MASLD and the gut–liver axis: from pathogenesis to treatment options. Nutrients. 2024;16(14). https://pubmed.ncbi.nlm.nih.gov/39057689/

10. Fang J., Yu C.H., Li X.J., et al. Unraveling the gut–liver axis: contribution of the microbiota to the pathogenesis of metabolic dysfunction-associated steatotic liver disease. Frontiers in Microbiology. 2025.

11. Xia J., Jin Y., Hong Y., et al. Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats: from endogenous dysbiosis to ceftriaxone-induced dysbiosis. Frontiers in Microbiology. 2025. https://doi.org/10.3389/fmicb.2025.1693247

12. Sanchez J.J., Namba M.D., Augur I.F., et al. Ceftriaxone alters gut microbiome composition and reduces alcohol consumption in male and female Sprague–Dawley rats. Alcohol. 2024.

13. Song Q., Zhang X., et al. Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a reanalysis of multiple studies. Frontiers in Cellular and Infection Microbiology. 2026.

14. Gao H., Shu Q., Chen J., et al. Antibiotic exposure exerts sex-dependent effects on the gut microbiota and the metabolism of short-chain fatty acids and amino acids in mice. mSystems. 2019;4(4). https://doi.org/10.1128/mSystems.00048-19

15. Stankiewicz-Drogon A., Skrzypczak-Zielinska M., Dobrowolska A., et al. A diet-induced model of gradual development of nonalcoholic fatty liver disease in rats with lipopolysaccharide secretion. Diagnostics. 2019;9(4):205. https://www.mdpi.com/2075-4418/9/4/205

16. Ferro D., Baratta F., Pastori D., et al. Heterogeneity of the gut microbiota in nonalcoholic fatty liver disease: a narrative review of factors, mechanisms, and clinical significance. Frontiers in Microbiology. 2025.

17. Rau M., Geier A., et al. Deciphering the gut–liver axis: a comprehensive scientific review of nonalcoholic fatty liver disease. Livers. 2024;4(3):32. https://www.mdpi.com/2673-4389/4/3/32

18. Yamamoto A., Kawaguchi T., et al. Investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and a retrospective observational study. Scientific Reports. 2024;14.

19. Oliphant K., Allen-Vercoe E., et al. Diet-induced metabolic changes in the human gut microbiome: implications for short-chain fatty acids, methylamines, and indoles. Gut Microbes. 2019.

20. Chambers E.S., Preston T., Frost G., Morrison D.J. Short-chain fatty acids—metabolites of the gut microbiota—and obesity. Current Nutrition Reports. 2018;7(4).